biotech

biotech Articles

Cara Therapeutics recently announced data from its late-stage trial in patients with chronic kidney disease. While there was a very positive reaction among investors, one analyst believes that this...
Inovio Pharmaceuticals shares dipped on Wednesday after it was announced that the firm’s partnership with AstraZeneca would be scaled back.
AnaptysBio has been called on to have as much as 82% upside in a Credit Suisse research report. There is a scenario in which the analyst even sees as much as 200% upside.
Cara shares jumped on Wednesday after the firm announced topline data from its late-stage trial in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus.
Kezar Life Sciences shares were absolutely crushed on Tuesday after the firm revealed data from its midstage trial in patients with systemic lupus erythematosus.
The May 15 short interest data have been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Despite the wearing down of hepatitis C drugs and the political climate targeting drug prices, this analyst sees stabilization and predictability in the base businesses of two key biotech leaders.
Tonix Pharmaceuticals shares jumped on Thursday after the firm announced that it has in-licensed a Phase 2 asset, TNX-1300 for the treatment of cocaine intoxication.
Ocular Therapeutix shares took a beating on Tuesday after the firm announced late-stage results for patients with primary open-angle glaucoma or ocular hypertension. These results come from the Phase...
BioCryst Pharmaceuticals shares were absolutely crushed in Tuesday’s session after the company announced late-stage results for its study in hereditary angioedema patients.
This is known as the world’s largest clinical cancer conference, and it always delivers new results on clinical trials and updated treatments in the field. Not to mention, this conference has the...
If there is one former Dow Jones industrial average leader that is in need of serious help, look no further than General Electric.
MacroGenics announced additional details of the results from the Phase 3 Sophia study of margetuximab in patients with HER2-positive metastatic breast cancer who have previously been treated with...
Iovance Biotherapeutics is one of the early big winners from ASCO. The firm announced updates from ongoing clinical trials including new interim data from studies of patients with advanced cervical...
Solid Biosciences shares were crumbling on Tuesday after the firm announced its first-quarter results and an update to its midstage Duchenne muscular dystrophy trial.